Literature DB >> 6334739

Interleukin abnormalities in recently active rheumatoid arthritis.

P Tan, A Shore, P Leary, E C Keystone.   

Abstract

Peripheral blood lymphocytes (PBL) from 14 patients with rheumatoid arthritis (RA) produced increased amounts of interleukin (IL) (p less than 0.05) as measured in a mouse thymocyte assay and showed enhanced proliferation in response to an IL containing supernatant (p less than 0.05) when compared with 9 age matched controls. Both enhanced IL production (p greater than 0.01) and responsiveness (p less than 0.002) were seen exclusively in a subgroup of 7 patients with a recent onset or exacerbation of their disease. PBL from RA patients with equally active disease which had been unchanged for more than 6 months produced and responded to IL normally. There was a direct correlation between IL production and responsiveness (r = 0.69, p less than 0.005). These 2 distinct IL abnormalities appear to reflect disease initiating or exacerbating factors in RA.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6334739

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  Is there a causal role for IL-1 in postmenopausal bone loss?

Authors:  R Pacifici
Journal:  Calcif Tissue Int       Date:  1992-04       Impact factor: 4.333

2.  Immunoregulatory lymphokines in rheumatoid joints. II. Production by and responsiveness to interleukin-2 of eluted synovial tissue cells.

Authors:  J Hovdenes; T Egeland
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

3.  Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate.

Authors:  A Barbier; J C Breliére; B Remandet; R Roncucci
Journal:  Ann Rheum Dis       Date:  1986-01       Impact factor: 19.103

4.  Immunotherapy of collagen-induced arthritis by a T-cell antiproliferative molecule.

Authors:  D J Spannaus-Martin; R Holmdahl; T F Kresina
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

5.  Interleukin 2 inhibitor in synovial fluid.

Authors:  P Emery; K C Gentry; A Kelso; I R Mackay
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

6.  Bone matrix constituents stimulate interleukin-1 release from human blood mononuclear cells.

Authors:  R Pacifici; A Carano; S A Santoro; L Rifas; J J Jeffrey; J D Malone; R McCracken; L V Avioli
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

7.  Cytokine enhancement of monocyte/synovial cell attachment to the surface of cartilage: a possible trigger of pannus formation in arthritis.

Authors:  H Ishikawa; O Ohno; R Saura; T Matsubara; T Kuroda; K Hirohata
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

8.  Alteration of interleukin-1 activity and the acute phase response in adjuvant arthritic rats treated with disease modifying antirheumatic drugs.

Authors:  K M Connolly; V J Stecher; E Danis; D J Pruden; T LaBrie
Journal:  Agents Actions       Date:  1988-08

9.  Enhanced interleukin 1 generation by monocytes in vitro is temporally linked to an early event in the onset or exacerbation of rheumatoid arthritis.

Authors:  A Shore; S Jaglal; E C Keystone
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.